Concludes Strategic Alternatives Review and Provides Update on Development of KER-065LEXINGTON, Mass., June 09, 2025 (GLOBE ...

After a major shareholder pushed back, Keros is returning half of its capital to investors in a move that Guggenheim analysts ...

JAR of Hope helps support a team of researchers and doctors who are aiming to eliminate Duchenne muscular dystrophy – a fatal ...

Disclosing new interim data from its Phase 1/2 AFFINITY DUCHENNE trial, Regenxbio (NASDAQ:RGNX) announced Thursday that its ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial. Updates ...

Interim results from a small group of children in a Phase I/II trial are essentially in line with that of Elevidys, according ...

Cardiac complications in Duchenne muscular dystrophy (DMD) are the result of cardiac muscle involvement that accompanies the ...

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from ...

Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

The campaign to commemorate the work of the Muscular Dystrophy Association was created in partnership with agency Yes&.